Last reviewed · How we verify
NCT02949726
Lymphatic and Systemic Immunity Changes in Post-radiation Lymphedema Development
Phase 1 trial testing Indocyanine Green (ICG) in Lymphedema in 80 participants. Completed in 1 October 2022.
1 October 2022
Quick facts
| Lead sponsor | The University of Texas Health Science Center, Houston |
|---|---|
| Phase | Phase 1 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 80 |
| Start date | 24 April 2017 |
| Primary completion | 1 October 2022 |
| Estimated completion | 1 October 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Indocyanine Green (ICG) — full drug profile →
- Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)
Conditions studied
- Lymphedema — all drugs for Lymphedema →
Sponsor
The University of Texas Health Science Center, Houston
Who can join
18 and older, female only, with Lymphedema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this study is to find out which immune molecules, cells, and genes are involved in the development of lymphedema (LE), so that medicines that target them can be considered for treating lymphedema. The hypothesis is that LE is a systemic, autoimmune-like disease that is initiated by inflammatory cytokines induced by surgery, radiation, and possibly chemotherapy in genetically susceptible patients.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Lymphatic function and anatomy in early stages of lipedema.
Rasmussen JC, Aldrich MB, Fife CE, Herbst KL, et al · · 2022 · cited 29× · PMID 35707862 · DOI 10.1002/oby.23458 -
The Development and Treatment of Lymphatic Dysfunction in Cancer Patients and Survivors.
Aldrich MB, Rasmussen JC, Fife CE, Shaitelman SF, et al · · 2020 · cited 20× · PMID 32823928 · DOI 10.3390/cancers12082280 -
Prediction of breast cancer-related lymphedema by dermal backflow detected with near-infrared fluorescence lymphatic imaging.
Aldrich MB, Rasmussen JC, DeSnyder SM, Woodward WA, et al · · 2022 · cited 14× · PMID 35816269 · DOI 10.1007/s10549-022-06667-4 -
Lymphatic pumping failure in the arm precedes dermal backflow and breast cancer-related lymphedema.
Aldrich MB, McWain ME, Shaitelman SF, Kuhns RE, et al · · 2026 · PMID 41703640 · DOI 10.1186/s13058-026-02231-w
Verify or expand the search:
- PubMed search for NCT02949726
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Indocyanine Green (ICG)
Trials testing the same drug.
- NCT07149207 — Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors · Phase 2 · recruiting
- NCT05735977 — Nephrogreen. Appearances of Exvivo Renal Tumours Under Near-infrared · NA · completed
- NCT04258566 — Electromagnetic Tracking and Optical Imaging With ICG for Hepatic Biopsies · NA · terminated
- NCT04511026 — Concurrent Use Lymphoseek & Indocyanine Green in Sentinel Lymph Node Detection in Endometrial Cancer · Phase 2 · terminated
- NCT02710240 — Indocyanine Green for Central Nervous System Tumors · Phase 1, PHASE2 · completed
Other recruiting trials for Lymphedema
Currently open trials in the same condition.
- NCT07489248 — Multimodal Ultrasound for Differentiating Lymphedema and Lipedema · recruiting
- NCT07448467 — Investigation of the Effectiveness of Progressive Resistance Exercise Training in the Management of Lymphedema. · NA · recruiting
- NCT02285868 — ATI Evidence-based Guide Investigating Clinical Services · active not recruiting
- NCT07414615 — Aerobic Training in Lower Extremity Lymphedema · NA · recruiting
- NCT06866197 — CONNECT: A Multi-Cohort, Prospective Investigation of the Symani® Surgical System · NA · recruiting
Other The University of Texas Health Science Center, Houston trials
Trials by the same sponsor.
- NCT04200729 — Povidone-iodine Irrigation for Prevention of Intra-abdominal Abscess in Pediatric Perforated Appendicitis: a Multi-cente · Phase 4 · not yet recruiting
- NCT07225062 — Improving HIV Prevention and Substance Use Post-Sexual Assault Services · NA · not yet recruiting
- NCT07396974 — Increasing Treatment Access in Trauma Exposed Children: Developing an Adapted Step One Intervention (RCT) · NA · not yet recruiting
- NCT07170163 — Navigating the Transition to Adulthood: A Dual Language Mobile App for Latino Youth With ASD and Their Families · NA · not yet recruiting
- NCT06915441 — Lipid Infusions to Optimize Nutrition Trial · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT02949726 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The University of Texas Health Science Center, Houston
- Last refreshed: 14 December 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02949726.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing